Invivyd

About Invivyd

Invivyd, Inc. creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, drug and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization from the U.S. FDA for a monoclonal antibody in its pipeline of innovative antibody candidates.